BCBS Tennessee IBD Laboratory Testing Coverage

Coverage Criteria

Not medically necessary / Not covered

The following tests DO NOT MEET COVERAGE CRITERIA for diagnosis or monitoring of IBD:

Serologic markers not covered: Use of serologic markers including, but not limited to, ANCA, ASCA, pANCA, anti-OmpC, anti-I2, anti-cBir1, ACCA IgA, ALCA IgG, AMCA IgG, and PKM2 for the workup and monitoring of inflammatory bowel disease does not meet coverage criteria.

listed explicitly in policy

Diagnostic algorithm-based panels not covered: Diagnostic algorithm-based testing that combines serologic, genetic, and inflammatory markers (for example, Prometheus® testing and similar multi-marker panels) does not meet coverage criteria for diagnosis or monitoring of IBD.

listed explicitly in policy

Genetic testing not covered: Genetic testing for IBD (routine genetic risk/marker testing) does not meet coverage criteria for diagnosis or monitoring of IBD.

listed explicitly in policy

Routine diagnostic use

Coverage stance summarized from guideline statements in this section:

Overall diagnostic role: Genetic and serologic molecular markers are not recommended for routine diagnosis or classification of Crohn's disease or ulcerative colitis; laboratory testing is complementary to clinical, endoscopic, radiologic, and histologic evaluation.

Derived from ACG, ECCO, and joint guideline statements

Adjunctive/supportive testing

Situations where serologic markers may have limited supporting role:

Supportive but limited utility: Serologic markers (for example ASCA, pANCA, antiglycan and antimicrobial antibodies including anti-OmpC and anti-CBir1) may be used adjunctively to support a diagnosis or to increase likelihood that an unclassified IBD-like case represents Crohn's disease, but their sensitivity is limited and the additional diagnostic value is small.

Meta-analysis and reviews indicate high specificity but low sensitivity

Pediatric/monogenic testing

Pediatric and VEO-IBD considerations:

Genetic testing in young/atypical patients: Genetic sequencing (targeted panels, whole exome sequencing, or whole genome sequencing in select cases) should be considered in very early-onset IBD (presentation <6 years) or in atypical/aggressive pediatric presentations (eg, infantile onset, consanguinity, recurrent infections, HLH, nonresponse to multiple IBD medications) to identify monogenic causes that may guide targeted therapy.

NASPGHAN guidance

Serum 7α-hydroxy-4-cholesten-3-one (7C4) has been studied as an indirect marker of bile acid deficiency and as an alternative to stool bile acid measurement, but the policy explicitly states that 7C4 is not recommended in the workup for IBD. The test may have utility in evaluating bile acid-related diarrhea or IBS phenotypes, but it is not supported for routine diagnostic evaluation or monitoring of inflammatory bowel disease.

Multiple professional guidelines conclude that routine serologic antibody testing and genetic testing are not recommended to establish the diagnosis or prognosis of Crohn's disease or ulcerative colitis. Guidance from the American College of Gastroenterology (ACG) and joint ECCO/ESGAR statements emphasize that diagnosis relies on clinical, endoscopic, radiologic and histologic evaluation and that genetic or serologic testing has insufficient evidence to be used routinely for classification or diagnostic confirmation.

Commercial multi-marker panels (for example, Prometheus IBD sgi and related Prometheus offerings) have been evaluated in the literature, but analyses and critiques indicate limited incremental predictive value for some components. Published critiques note that much of the predictive signal from these panels may derive from a few widely available, lower-cost components rather than the full algorithmic panel; consequently, the policy cites limited evidence that these commercial diagnostic algorithm-based tests improve clinically actionable decision-making for routine IBD care.

The policy lists commonly referenced serologic markers and diagnostic algorithm-based panels studied in IBD. Serologic markers include ANCA, ASCA, pANCA, anti-OmpC, anti-I2, anti-CBir1, ACCA (IgA), ALCA (IgG), AMCA (IgG), and PKM2. Commercial multi-marker tests (for example, Prometheus IBDsgi, Monitr, and PredictrPK IFX) combine subsets of these antibodies with genetic or inflammatory markers in algorithmic panels that have been described in the literature.

The policy states that routine use of serologic markers to establish a diagnosis or determine prognosis in ulcerative colitis and to establish diagnosis of Crohn's disease is not indicated. ACG guidance specifically recommends against serologic antibody testing to establish or rule out UC and states that genetic testing is not indicated to establish CD; the overall message is that serologic assays may provide supportive information but are not sufficient or recommended for routine diagnostic or prognostic use.

Covered Indications

Use of general inflammatory markers (fecal calprotectin, lactoferrin, ESR, CRP) to assess disease activity and to differentiate IBD from IBS

Use of general inflammatory markers to assess disease activity and to differentiate IBD from IBS:

Preferred inflammatory markers: Fecal calprotectin, fecal lactoferrin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) are commonly correlated with disease activity in IBD and may be used to help differentiate IBD from irritable bowel syndrome and to monitor disease activity and response to treatment.

Referenced as commonly correlated with disease activity and discussed in related guidance

Evaluation of suspected monogenic VEO-IBD or atypical pediatric presentations — Genetic testing (targeted panels, WES/WGS) per NASPGHAN guidance.

Evaluation of suspected monogenic VEO-IBD or atypical pediatric presentations:

When to perform genetic testing: Genetic testing (targeted gene panels, with reflex to whole exome or whole genome sequencing when indicated) should be performed or considered under specialist evaluation (pediatric gastroenterology/immunology) for very early-onset IBD (<6 years) or in cases with phenotype consistent with known defects, history of consanguinity, abnormal immunology, or other features suggesting a monogenic disorder.

Provider Actions and Prior Authorization

Prior Authorization

Prior authorization and benefit verification — Tests not meeting coverage criteria

Tests listed as not meeting coverage criteria (including serologic markers, diagnostic algorithm–based panels, and genetic testing) are not covered. Verify member benefits and applicable medical necessity prior to ordering. When government (NCD/LCD) policy conflicts with this policy, the government policy governs. Laboratories performing laboratory-developed tests (LDTs) must validate those assays and comply with CLIA high-complexity requirements; lack of appropriate validation or CLIA compliance may affect coverage.

Denial triggers include serologic markers (ANCA, ASCA, pANCA, anti-OmpC, anti-I2, anti-cBir1, ACCA, ALCA, AMCA, PKM2) and algorithmic panels combining serologic, genetic, and inflammation markers (eg, Prometheus offerings).
Genetic testing for IBD does not meet coverage criteria.
Verify individual member benefits and Medicare/Medicaid specifications before ordering; government policy (NCD/LCD) supersedes this policy when applicable.
Labs must perform required validation for LDTs and comply with CLIA '88 for high-complexity testing; FDA clearance is not required for clinical use but lack of proper validation may affect reimbursement.
If ordering alternative tests to standard inflammatory markers (CRP, ESR, fecal calprotectin), document the clinical rationale in the medical record.

Ordering Requirements

Documentation Required

ORDERING REQUIREMENTS — verify benefits and document indication

Verify member benefits and document clinical indication prior to ordering; standard inflammatory tests (CRP, ESR, fecal calprotectin) are established in practice for assessment and differentiation.

Chunk 3: 'Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.'
Chunk 11: 'Fecal calprotectin, lactoferrin, ESR and CRP have each been correlated with disease activity... Fecal calprotectin has been shown to be useful to help differentiate the presence of IBD from irritable bowel syndrome and in monitoring disease activity and response to treatment.'

Note

ORDERING REQUIREMENTS — specialist‑directed genetic testing in VEO‑IBD

Genetic sequencing for VEO‑IBD should be considered or performed by specialists (pediatric gastroenterology or immunology) with expertise in monogenic IBD evaluation.

Chunk 28 (NASPGHAN): '…genetic sequencing is often necessary... Targeted panels should be performed first in cases of infantile onset... WES is most often performed in the setting of a negative targeted panel... WGS should be reserved for cases in which WES is negative.'

Not Covered

The policy identifies a list of tests and panels that do not meet coverage criteria for the diagnosis or monitoring of IBD. These include serologic antibody panels (e.g., ANCA, ASCA, pANCA, anti-OmpC, anti-I2, anti-CBir1, ACCA, ALCA, AMCA, PKM2), diagnostic algorithm-based panels that combine serologic, genetic, and inflammatory markers (such as Prometheus® testing), and genetic testing for IBD.

Professional society guidance summarized in the policy supports the stance that routine serologic or genetic testing is not indicated for diagnosis or prognosis in typical adult presentations of IBD. ECCO and ACG statements explicitly recommend against routine use of these molecular markers for classification or prognostication in clinical practice due to limited sensitivity and modest predictive yield.

The document notes that many laboratory-developed tests (LDTs) are not FDA-approved and are instead regulated under CLIA as high-complexity tests. While this section does not list additional specific tests as not covered, it emphasizes that LDTs must be validated and performed in appropriately certified laboratories under CLIA requirements.

While the policy critiques commercial panels and cites literature questioning the added value of some components, the referenced critiques do not explicitly single out additional tests as noncovered. Instead, the policy uses these analyses to support a cautious interpretation of commercial algorithmic panels' clinical utility and to justify the not‑medically‑necessary designation for diagnostic algorithm-based testing when used routinely.

Definitions

Inflammatory bowel disease (IBD) — inv-27: definition

DefinitionInflammatory bowel disease (IBD) comprising Crohn's disease and ulcerative colitis

ComponentsUlcerative colitis: relapsing/remitting mucosal inflammation of the colon; Crohn's disease: patchy transmural inflammation that can cause fistulae and strictures

Clinical relevanceDiagnosis relies on clinical, endoscopic, radiologic, histologic, and laboratory evaluation

ASCA — inv-28: definition

DefinitionAnti‑Saccharomyces cerevisiae antibody (ASCA)

TargetAntibody against mannan from baker's yeast (Saccharomyces cerevisiae)

Frequency Limits

Frequency limits — inv-39: summary

Frequency guidanceNo explicit frequency limits provided in these sections of the policy

ImplicationOrdering and reimbursement should follow benefit verification and clinical necessity since the policy does not specify periodicity

Related noteStandard inflammatory tests (CRP, ESR, fecal calprotectin) are referenced elsewhere as commonly used but no frequency limits are stated here

Frequency limits — inv-40: placeholder

Frequency guidance placeholderNo frequency limits or test‑specific periodicity provided (empty summary)

Effective date notePolicy adopts Avalon recommendations effective 7/1/2023; no frequency rules were added in these excerpts

Background

Inflammatory bowel disease (IBD) comprises two major disorders — Crohn's disease and ulcerative colitis — that have distinct pathologic and clinical features. The diagnosis of CD or UC is based on a combination of clinical presentation and complementary investigations including biochemical, stool, endoscopic, cross-sectional imaging, and histological studies; no single laboratory test provides a definitive diagnosis.

OpenPayer

Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Coverage Criteria

Covered Indications

Provider Actions and Prior Authorization

Ordering Requirements

Not Covered

Definitions

Frequency Limits

Background